SCHEMBL9944310

SCHEMBL9944310

CCOc1c(Cl)cc(C(=O)Nc2ccc(C=O)cc2)cc1OC(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
RAB9A P51151 3/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 5/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 3/20 0.48
PLAU P00749 2/20 0.46
ALDH1A1 P00352 6/20 0.46
MAPK1 P28482 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
TP53 P04637 1/20 0.45
LMNA P02545 3/20 0.45
HPGD P15428 2/20 0.45
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944330 0.92 GAA (0.51) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944293 0.89 TAS1R3 (0.53) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944285 0.88 TAS1R3 (0.57) MEN1KMT2AMAPTGAAPLAU
SCHEMBL1458087 0.87 MEN1 (0.60) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944214 0.87 MEN1 (0.52) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944331 0.86 RAB9A (0.49) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944288 0.86 RAB9A (0.49) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944292 0.84 TOP1 (0.49) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944319 0.84 MAPT (0.48) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL9944350 0.84 MAPT (0.50) MEN1KMT2ARAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MEN1 4809/4885KMT2A 1418/4885RAB9A 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.